Abstract | BACKGROUND: METHODS: Patients affected by R/M sSCC, treated with pan-HER inhibitor dacomitinib or with platinum-based chemotherapy with cetuximab (CT-cet) from 2010 to 2016, were considered. PD-L1 expression was assessed with immunohistochemistry on tumor cells (TCs) and on microenvironment (TC and tumor-infiltrating lymphocyte [IC] scores, respectively). Prognostic role of PD-L1 and the correlation with response to EGFR inhibitors and survival were analyzed. RESULTS: Twenty-eight R/M sSCCs were analyzed (19 treated with dacomitinib, 9 with CT-cet). TC and IC were negative in 82 and 45% of cases, respectively; 15% sSCCs were both TC and IC positive. Progression-free survival (PFS) was longer in IC-positive cases (median 7.5 months vs. 2.1 in IC0, p = 0.02). No statistically significant differences were observed between PD-L1 expression and both overall survival and response rates. CONCLUSION: PD-L1 expression in microenvironment predicted better PFS. The combination of EGFR inhibitors and ICB could help deepening the knowledge about the interrelations between the EGFR and PD-1/PD-L1 pathways.
|
Authors | Stefano Cavalieri, Federica Perrone, Massimo Milione, Alba Bianco, Salvatore Alfieri, Laura D Locati, Cristiana Bergamini, Carlo Resteghini, Donata Galbiati, Francesca Platini, Lisa Licitra, Paolo Bossi |
Journal | Oncology
(Oncology)
Vol. 97
Issue 2
Pg. 112-118
( 2019)
ISSN: 1423-0232 [Electronic] Switzerland |
PMID | 31112973
(Publication Type: Journal Article)
|
Copyright | © 2019 S. Karger AG, Basel. |
Chemical References |
- B7-H1 Antigen
- CD274 protein, human
- ErbB Receptors
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- B7-H1 Antigen
(metabolism)
- Carcinoma, Squamous Cell
(drug therapy, metabolism, pathology)
- ErbB Receptors
(antagonists & inhibitors)
- Female
- Humans
- Immunohistochemistry
- Male
- Middle Aged
- Neoplasm Metastasis
- Recurrence
- Retrospective Studies
- Skin Neoplasms
(drug therapy, metabolism, pathology)
- Survival Analysis
- Tumor Microenvironment
|